M
Mary Anne Dooley
Researcher at University of North Carolina at Chapel Hill
Publications - 152
Citations - 17833
Mary Anne Dooley is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Lupus erythematosus & Lupus nephritis. The author has an hindex of 55, co-authored 142 publications receiving 15392 citations.
Papers
More filters
Journal ArticleDOI
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more
TL;DR: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
Journal ArticleDOI
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
Ellen M. Ginzler,Mary Anne Dooley,Cynthia Aranow,Mimi Y. Kim,Jill P. Buyon,Joan T. Merrill,Michelle Petri,Gary S. Gilkeson,Daniel J. Wallace,Michael H. Weisman,Gerald B. Appel +10 more
TL;DR: In this 24-week randomized, open-label, noninferiority trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Journal ArticleDOI
Mortality in systemic lupus erythematosus.
Sasha Bernatsky,J. F. Boivin,Lawrence Joseph,S. Manzi,Ellen M. Ginzler,Dafna D. Gladman,Murray B. Urowitz,Paul R. Fortin,M. Petri,Susan G. Barr,Caroline Gordon,Sang Cheol Bae,David A. Isenberg,Asad Zoma,Cynthia Aranow,Mary Anne Dooley,Ola Nived,Gunnar Sturfelt,Kristjan Steinsson,Graciela S. Alarcón,J L Senécal,Michel Zummer,John G. Hanly,Stephanie Ensworth,Janet E. Pope,Steven M. Edworthy,Anisur Rahman,J Sibley,Hani El-Gabalawy,Timothy McCarthy,Y. St. Pierre,Ann E. Clarke,Rosalind Ramsey-Goldman +32 more
TL;DR: The Lupus Survival Study Group data are reviewed and particularly the data from the State University of New York Health Science Center at Brooklyn, NY is reviewed.
Journal ArticleDOI
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel,Gabriel Contreras,Mary Anne Dooley,Ellen M. Ginzler,David A. Isenberg,David Jayne,Lei Shi Li,Eduardo Mysler,Jorge Sánchez-Guerrero,Neil Solomons,David Wofsy,Carlos Abud,Sharon G. Adler,Graciela S. Alarcón,Elisa N. Albuquerque,Fernando Almeida,Alejandro Alvarellos,Gerald B. Appel,Hilario Avila,Cornelia Blume,Ioannis Boletis,Alain Bonnardeaux,Alan Braun,Jill P. Buyon,Ricard Cervera,Nan Chen,Shun-Le Chen,António Gomes Da Costa,Razeen Davids,David D'Cruz,Enrique de Ramón,Atul Deodhar,Andrea Doria,Bertrand Dussol,Paul Emery,Justus Fiechtner,Jürgen Floege,Hilda Fragoso-Loyo,Richard Furie,Rozina Ghazalli,Cybele Ghossein,Gary S. Gilkeson,EM Ginzler,Caroline Gordon,Jennifer M. Grossman,Jieruo Gu,Loïc Guillevin,Pierre Yves Hatron,Gisela Herrera,Falk Hiepe,Frédéric Houssiau,Osvaldo Hübscher,Claudia Hura,Joshua Kaplan,Gianna Mastroianni Kirsztajn,Emese Kiss,Ghazali Ahmad Kutty,Maurice Laville,Maria Lazaro,Oliver Lenz,Leishi Li,Liz Lightstone,Sam Lim,Michel Malaise,Susan Manzi,Juan Carlos Marcos,Olivier Meyer,Pablo Monge,Saraladev Naicker,Nathaniel Neal,Michael Neuwelt,Kathy Nicholls,Nancy J. Olsen,José Ordi-Ros,Barbara E. Ostrov,Manuel Pestana,Michelle Petri,G. Pokorny,Jacques Pourrat,Jiaqi Qian,Jai Radhakrishnan,Brad H. Rovin,Julio Sanchez Roman,Joseph C. Shanahan,William Shergy,Fotini Skopouli,Alberto Spindler,Christopher Striebich,Robert Sundel,Charles R. Swanepoel,Yen Tan Si,Guillermo Tate,Vladimír Tesaŕ,Mohamed Tikly,Haiyan Wang,Rosnawati Yahya,Xueqing Yu,Fengchun Zhang,Diana Zoruba +98 more
TL;DR: Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Journal ArticleDOI
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: It is indicated that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.